A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Victor Moyo, MD
Merrimack Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Universito of Birmingham Atalabama
Birmingham, Alabama, United States
- Arizona Oncology Associates
Tucson, Arizona, United States
- Arizona Oncology Associates
Tuscon, Arizona, United States
- Marin Cancer Center
Greenbrae, California, United States
- Pmk Medical Group
Oxnard, California, United States
- Wilshire Oncology Medical Group
Rancho Cucamonga, California, United States
- Florida Cancer Research Institute
Plantation, Florida, United States
- Piedmont Healthcare
Altanta, Georgia, United States
- Piedmont Fayette Hospital
Fayetteville, Georgia, United States
- Georgia Cancer Specialists
Marietta, Georgia, United States
- University of Chicago
Chicago, Illinois, United States
- Illinois Cancer Specialists
Niles, Illinois, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Beaumont Health Systems
Royal Oak, Michigan, United States
- Comprehensive Cancer Centers of Nevada
Henderson, Nevada, United States
- Cooper Cancer Institute
Voorhees Township, New Jersey, United States
- University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
- Memorial Medical Center
Las Cruces, New Mexico, United States
- Northwest Cancer Specialists
Portland, Oregon, United States
- Cancer Center of the Carolinas
Greenville, South Carolina, United States
- Texas Oncology - Amarillo
Amarillo, Texas, United States
- Texas Oncology-Austin Central
Austin, Texas, United States
- Texas Oncology - Bedford
Bedford, Texas, United States
- Texas Oncology - Baylor Charles A Sammons Cancer Center
Dallas, Texas, United States
- Texas Oncology - Dallas
Dallas, Texas, United States
- Texas Oncology - Medical City
Dallas, Texas, United States
- Texas Oncology -El Paso
El Paso, Texas, United States
- Texas Oncology - Garland
Garland, Texas, United States
- Texas Oncology - Memorial City
Houston, Texas, United States
- Texas Oncology - Lewisville
Lewisville, Texas, United States
- Texas Oncology - Mcallen
McAllen, Texas, United States
- Texas Oncology Plano East
Plano, Texas, United States
- Cancer Care Centers of South Texas
San Antonio, Texas, United States
- Texas Oncology - Tyler
Tyler, Texas, United States
- Virginia Oncology Associates
Norfolk, Virginia, United States
- Puget Sound Cancer Center
Seattle, Washington, United States
- Yakima Valley Memorial Hospital
Yakima, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2011
- Primary completion
- 31 Dec 2013
- Completion
- 30 Jun 2014
- Last update posted
- 3 May 2016
- Registered enrollment
- 196
- Registry id
- NCT01421472
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.